Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 94, Issue , 2015, Pages 135-140

  Solymosi, Tamás ^a   Angi, Réka ^a   Basa Dénes, Orsolya ^a   Ránky, Soma ^a   Ötvös, Zsolt ^a   Glavinas, Hristos ^a   Filipcsei, Genovéva ^a   Heltovics, Gábor ^b  

^a NANGENEX INC   (Hungary)

^b Druggability Technologies Holdings Ltd Tower Business Centre   (Malta)

Author keywords

Continuous flow precipitation; Enhanced bioavailability; Sirolimus

Indexed keywords

RAPAMYCIN; COLLOID; DRUG DOSAGE FORM; EXCIPIENT; IMMUNOSUPPRESSIVE AGENT; NANOPARTICLE; SOLVENT;

ANIMAL EXPERIMENT; APPARENT PERMEABILITY; ARTICLE; COLLOID; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIGHT SCATTERING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; RAT; SCALE UP; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET SPECTROPHOTOMETRY; ULTRAVIOLET SPECTROSCOPY; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG DOSAGE FORM; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRECIPITATION; PROCEDURES; SOLUBILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DOSAGE FORMS; EXCIPIENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; NANOTECHNOLOGY; RATS, WISTAR; SIROLIMUS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84930676723     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.05.010     Document Type: Article

References (21)

1. S.N. Sehgal Rapamune (Sirolimus, rapamycin): an overview and mechanism of action Ther. Drug Monit. 17 1995 660 665
2. P. Simamora, J.M. Alvarez, and S.H. Yalkowsky Solubilization of rapamycin Int. J. Pharm. 213 2001 25 29
3. P.-C. Luo, Y. Cheng, Y. Jin, W.-H. Yang, and J.-S. Ding Fast liquid mixing by cross-flow impingement in millimeter channels Chem. Eng. Sci. 62 2007 6178 6190
4. S. Bai, S.M. Stepkowski, B.D. Kahan, and L.J. Brunner Metabolic interaction between cyclosporine and Sirolimus Transplantation 77 2004 1507 1512
5. V.C. McAlister, K. Mahalati, K.M. Peltekian, A. Fraser, and A.S. MacDonald A clinical pharmacokinetic study of Tacrolimus and Sirolimus combination immunosuppression comparing simultaneous to separated administration Ther. Drug Monit. 24 2002 346 350
6. R.W. Yatscoff Pharmacokinetics of rapamycin Transpl. Proc. 28 1996 970 973
7. K. Mahalati, and B.D. Kahan Clinical pharmacokinetics of Sirolimus Clin. Pharmacokinet. 40 2001 573 585
8. W.M. Bennett The nephrotoxicity of immunosuppressive drugs Clin. Nephrol. 43 Suppl. 1 1995 S3 S7
9. D.J. Trepanier, H. Gallant, D.F. Legatt, and R.W. Yatscoff Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update Clin. Biochem. 31 1998 345 351
10. A.M. Marsland, and C.E. Griffiths The macrolide immunosuppressants in dermatology: mechanisms of action Eur. J. Dermatol.: EJD 12 2002 618 622
11. B. Madke Topical rapamycin (Sirolimus) for facial angiofibromas Indian Dermatol. Online J. 4 2013 54 57
12. L. Peng, A.D. Mendelsohn, T.J. LaTempa, S. Yoriya, C.A. Grimes, and T.A. Desai Long-term small molecule and protein elution from TiO2 nanotubes Nano Lett. 9 2009 1932 1936
13. S. Bisht, G. Feldmann, J.B. Koorstra, M. Mullendore, H. Alvarez, C. Karikari, M.A. Rudek, C.K. Lee, A. Maitra, and A. Maitra In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities Mol. Cancer Ther. 7 2008 3878 3888
14. E. Bertelmann, and U. Pleyer Immunomodulatory therapy in ophthalmology - is there a place for topical application? Ophthalmol. J. Int. D'ophtalmol. Int. J. Ophthalmol. Z. Augenheilkunde 218 2004 359 367
15. M.S. Kim, J.S. Kim, H.J. Park, W.K. Cho, K.H. Cha, and S.J. Hwang Enhanced bioavailability of Sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process Int. J. Nanomed. 6 2011 2997 3009
16. R. Angi, T. Solymosi, Z. Otvos, B. Ordasi, H. Glavinas, G. Filipcsei, G. Heltovics, and F. Darvas Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties Eur. J. Pharm. Biopharm.: Official J. Arbeitsgemeinschaft Pharm. Verfahrenstech. e.V 86 2014 361 368
17. W.A. Niesz, M. Groualle, Zs. Ötvös, F. Darvas, Instrument and Process for Nanoparticles Production in Continuous Flow Mode, NanGenex Inc., US 8,540,939, 2011.
18. M. Kansy, F. Senner, and K. Gubernator Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 41 1998 1007 1010
19. S. Bendels, O. Tsinman, B. Wagner, D. Lipp, I. Parrilla, M. Kansy, and A. Avdeef PAMPA - excipient classification gradient map Pharm. Res. 23 2006 2525 2535
20. K.A. Youdim, A. Avdeef, and N.J. Abbott In vitro trans-monolayer permeability calculations: often forgotten assumptions Drug Discovery Today 8 2003 997 1003
21. R.W. Yatscoff, P. Wang, K. Chan, D. Hicks, and J. Zimmerman Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations Ther. Drug Monit. 17 1995 666 671